Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Comment by TheBearInTheWoodson Apr 15, 2021 6:40pm
256 Views
Post# 33008082

RE:RE:still a need for COVID therapeutics

RE:RE:still a need for COVID therapeutics

The Government of Canada is working in collaboration with Canada's top life sciences industry leaders and scientist/research advisors with expertise in drug research and development and commercialization, to support the work of Canada's COVID-19 response. Until we can immunize Canadians on a national scale with an effective vaccine, developing or producing treatments for those who contract this virus is of critical importance. The right therapeutic technologies and drugs will save lives and limit the impacts of this pandemic

The COVID-19 Therapeutics Task Force will provide expert advice to the Government of Canada on COVID-19 therapeutics. They will assess and prioritize COVID-19 therapeutic projects seeking government support. The Task Force has seven core members, including two co-chairs, drawn from research and business leaders who have proven ability to bring new therapies to market in Canada and science advisor members who will review and provide advice on projects within their area of expertise.

The primary federal authoritative source of information for all Canadians on COVID-19 is Canada.ca/coronavirus, as well as the COVID-19 Information Line at 1-833-784-4397. Canadians should refer to these resources for regularly updated information and guidance.

<< Previous
Bullboard Posts
Next >>